scholarly journals The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients

2019 ◽  
Vol 10 (2) ◽  
pp. 368-377 ◽  
Author(s):  
Debora Basile ◽  
Annamaria Parnofiello ◽  
Maria Grazia Vitale ◽  
Francesco Cortiula ◽  
Lorenzo Gerratana ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Advanced Pancreatic Cancer ◽  
Impact Study ◽  
Early Loss ◽  
The Impact

The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy

2020 ◽  
pp. 1-8 ◽  
Author(s):  
Shinya Uemura ◽  
Takuji Iwashita ◽  
Hironao Ichikawa ◽  
Yuhei Iwasa ◽  
Naoki Mita ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Tumour Size ◽  
Advanced Pancreatic Cancer ◽  
Significant Risk ◽  
Skeletal Muscle Index ◽  
Significant Difference ◽  
The Impact

Abstract Sarcopenia, defined as decrease in skeletal muscle mass (SMM) and strength, might be associated with reduced survival. We investigated the impact of sarcopenia and decrease in SMM in patients with advanced pancreatic cancer during FOLFIRINOX (FX) therapy. Consecutive sixty-nine patients who received FX were evaluated. Skeletal muscle index (SMI) (cm2/m2) was used to evaluate SMM. The cut-off value of sarcopenia was defined as SMI <42 for males and <38 for females, based on the Asian Working Group for sarcopenia criteria. Sarcopenia was diagnosed in thirty-three (48 %) subjects. Comparison of baseline characteristics of the two groups (sarcopenia group: non-sarcopenia group) showed a significant difference in sex, tumour size and BMI. There was no significant difference in the incidence of adverse events with grades 3–5 and progression-free survival (PFS) during FX between the two groups (PFS 8·1 and 8·8 months; P = 0·88). On the multivariate analysis, progressive disease at the first follow-up computed tomography (hazard ratio (HR) 3·87, 95 % CI 1·53, 9·67), decreased SMI ≥ 7·9 % in 2 months (HR 4·02, 95 % CI 1·87, 8·97) and carcinoembryonic antigen ≥ 4·6 (HR 2·52, 95 % CI 1·10, 6·11) were significant risk factors associated with poor overall survival (OS), but sarcopenia at diagnosis was not. OS in patients with decreased SMI of ≥7·9 % and <7·9 % were 10·9 and 21·0 months (P < 0·01), respectively. In conclusion, decrease in SMM within 2 months after the initiation of chemotherapy had significantly shorter OS, although sarcopenia at diagnosis did not affect OS. Therefore, it might be important to maintain SMM during chemotherapy for a better prognosis.

Mo1358 THE IMPACT OF SKELETAL MUSCLE MASS LOSS IN PATIENTS WITH ADVANCED PANCREATIC CANCER DURING FOLFIRINOX

2020 ◽  
Vol 158 (6) ◽  
pp. S-863
Author(s):  
Shinya Uemura ◽  
Takuji Iwashita ◽  
Hironao Ichikawa ◽  
Yuhei Iwasa ◽  
Naoki Mita ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Mass Loss ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Advanced Pancreatic Cancer ◽  
Muscle Mass Loss ◽  
The Impact

Early loss of skeletal muscle mass as prognostic factor in metastatic pancreatic cancer patients

Nutrition ◽  
2018 ◽  
Vol 50 ◽  
pp. e9-e10
Author(s):  
D. Basile ◽  
A. Bacco ◽  
A. Parnofiello ◽  
M.G. Vitale ◽  
F. Cortiula ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Metastatic Pancreatic Cancer ◽  
Early Loss

Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy

2019 ◽  
Vol 71 (7) ◽  
pp. 1100-1107 ◽  
Author(s):  
Hee Seung Lee ◽  
Si Young Kim ◽  
Moon Jae Chung ◽  
Jeong Youp Park ◽  
Seungmin Bang ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Muscle Mass ◽  
Poor Prognosis ◽  
Skeletal Muscle Mass ◽  
Advanced Pancreatic Cancer ◽  
Second Line

scholarly journals Early loss of skeletal muscle mass (LSMM) as prognostic factor in metastatic pancreatic cancer (PC) patients

2017 ◽  
Vol 28 ◽  
pp. vi49
Author(s):  
D. Basile ◽  
A. Parnofiello ◽  
M.G. Vitale ◽  
F. Cortiula ◽  
S.K. Garattini ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Prognostic Factor ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Metastatic Pancreatic Cancer ◽  
Early Loss

scholarly journals Skeletal muscle mass as a prognostic indicator in resected pancreatic cancer patients

2017 ◽  
Vol 28 ◽  
pp. iii74
Author(s):  
Jongchan Lee ◽  
Jong-Chan Lee ◽  
In-Kuk Cho ◽  
Jaihwan Kim ◽  
Jin-Hyeok Hwang
Keyword(s):  
Skeletal Muscle ◽  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Prognostic Indicator

scholarly journals The impact of skeletal muscle mass on survival outcome in biliary tract cancer patients

PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0204985 ◽  
Author(s):  
Panita Limpawattana ◽  
Daris Theerakulpisut ◽  
Kosin Wirasorn ◽  
Aumkhae Sookprasert ◽  
Narong Khuntikeo ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Skeletal Muscle Mass ◽  
Survival Outcome ◽  
Tract Cancer ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document